Clinical Trials in Philadelphia

Showing 1221-1240 of 20,904 trials

Deucravacitinib for the Treatment of Palmoplantar Pustulosis

NCT05710185

A prospective, single-arm, open-label trial of deucravacitinib 6 mg daily in patients with PPP. All participants will receive deucravacitinib 6 mg daily for 24 weeks, with study visits every 4 weeks.

Palmoplantar Pustulosis

Brigham and Women's Hospital3 participantsStarted Jul 2023

Boston, Massachusetts, United States • Philadelphia, Pennsylvania, United States

Active Not RecruitingPhase 3< 1 mile

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

NCT04512235

AL (or light chain) amyloidosis begins in the bone marrow where abnormal proteins misfold and create free light chains that cannot be broken down. These free light chains bind together to form amyloid fibrils that build up in the extracellular space of organs, affecting the kidneys, heart, liver, spleen, nervous system and digestive tract. The primary purpose of this study is to determine whether CAEL-101, a monoclonal antibody that removes AL amyloid deposits from tissues and organs, improves overall survival, reduces cardiovascular related hospitalizations and it is safe and well tolerated in patients with stage IIIa AL amyloidosis.

AL Amyloidosis

Alexion Pharmaceuticals, Inc.281 participantsStarted Nov 2020

Scottsdale, Arizona, United States • Duarte, California, United States • Palo Alto, California, United States +107 more locations

Deucravacitinib for the Treatment of Palmoplantar Pustulosis

A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

Find Trials by Condition in Philadelphia

Phase I Pilot Study of Biodistribution, Metabolism and Excretion of Novel Radiotracer [18F]Fluorthanatrace (FTT) by PET/CT

A Clinical Trial Evaluating the Safety and Efficacy of a Single Subretinal Injection of AGTC-501 in Participants With XLRP

Long-Term Follow-Up of Patients Who Have Participated in Children's Oncology Group Studies

Study to Evaluate the Maximal Use of Ruxolitinib Cream in Adult and Adolescent Participants With Hidradenitis Suppurativa

Behavioral and/or Mirabegron to Treat Urinary Symptoms in Parkinson Disease

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

A Study of DB-1310 in Advanced/Metastatic Solid Tumors

A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular Carcinoma

Expanded Access Program of Neladalkib (NVL-655) for Patients With Advanced ALK+ NSCLC or Other ALK+ Solid Tumors

Non-invasive Vagal Stimulation for Frequent Premature Ventricular Complexes

A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (PD) Participants With Motor Fluctuations

A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms

A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults

AURA-IPF: A Randomized Phase 2 Study to Evaluate the Safety and Efficacy of AP02 (Nintedanib Solution) in IPF

A Study of Encorafenib Plus Cetuximab Taken Together With Pembrolizumab Compared to Pembrolizumab Alone in People With Previously Untreated Metastatic Colorectal Cancer

Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients

DIAMOND AF Post-Approval Study

A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma